{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:40:07Z","timestamp":1774330807412,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81402945"],"award-info":[{"award-number":["81402945"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Major Scientific and Technological Special Project","award":["2013ZX09303001"],"award-info":[{"award-number":["2013ZX09303001"]}]},{"name":"Scientific Research Foundation for the Returned Overseas Chinese Scholars in Tianjin","award":["2015-31"],"award-info":[{"award-number":["2015-31"]}]},{"name":"Natural Science Foundation of Tianjin Medical University"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.leukres.2017.01.025","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T07:30:23Z","timestamp":1485329423000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"56","author":[{"given":"Huilai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhe","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Pan-Hammarstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.01.025_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","article-title":"The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Armitage","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'connor","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000) (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem. J"},{"key":"10.1016\/j.leukres.2017.01.025_bib0035","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0040","first-page":"193","article-title":"Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice","volume":"63","author":"Liu","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.leukres.2017.01.025_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2013.03.059","article-title":"Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells","volume":"434","author":"Qiao","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.leukres.2017.01.025_bib0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","article-title":"Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells","volume":"68","author":"Zhou","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.leukres.2017.01.025_bib0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0060","first-page":"1503","article-title":"Antitumor activity of Chidamide in hepatocellular carcinoma cell lines","volume":"5","author":"Wang","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.leukres.2017.01.025_bib0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1158\/0008-5472.CAN-11-3248","article-title":"DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory","volume":"72","author":"Raynal","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.025_bib0070","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2009-11-256354","article-title":"Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.025_bib0075","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.025_bib0080","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.025_bib0085","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10495-006-0283-6","article-title":"Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells","volume":"11","author":"Gillespie","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2017.01.025_bib0090","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2017.01.025_bib0095","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2017.01.025_bib0100","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-09-3028","article-title":"Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage","volume":"70","author":"Conti","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.025_bib0105","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1078-0432.CCR-15-0351","article-title":"Correction: combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma","volume":"21","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.025_bib0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.leukres.2017.01.025_bib0115","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin. Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:18:34Z","timestamp":1655381914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261730036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":23,"alternative-id":["S014521261730036X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.025","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}